Table 1 Patient characteristics

From: Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias

Characteristic Diagnosis
  MDS ALL AML CMML
Number of patients 446 385 1314 58
Age 64 (19–87) 41 (13–92) 59 (10–87) 65 (28–80)
PB blast (%) 1 (0–28) 32 (0–100) 23 (0–99) 1 (0–9)
BM blast (%) 14 (0–29) 86 (0–100) 48 (0–98) 7 (0–24)
Platelet count ( × 109/l) 41 (2–597) 50 (4–485) 48 (1–2292) 52 (7–492)
Lymphocyte count ( × 106/l) 1296 (54–34 486) 1837 (0–54 575) 1708 (0–39 060) 2040 (391–15 768)
LDH, U/l 652 (212–13 688) 1294 (268–42 001) 1035 (25–39 243) 811 (290–3212)
B2M, mg/l 2.8 (0.8–15.8) 3.0 (0–50.5) 2.8 (0–31.3) 4.1 (1.22–15)
Cytogenetics a
 Favorable 11 (3%) 16 (4%) 175 (31%) 0
 Intermediate 244 (55%) 271 (76%) 803 (62%) 49 (85%)
 Unfavorable 188 (42%) 71 (20%) 324 (25%) 9 (15%)
Response to therapy
 CR 227 (51%) 332 (90%) 745 (58%) 24 (41%)
 Other 215 (49%) 38 (10%) 547 (42%) 34 (59%)
Performance status
 0–2 422 (95%) 358 (95%) 1165 (90%) 52 (90%)
 3, 4 23 (5%) 17 (5%) 132 (10%) 6 (10%)
AHD
 Absent 144 (33%) 344 (93%) 816 (63%) 11 (19%)
 Present 297 (67%) 25 (7%) 481 (37%) 46 (81%)
  1. Data are presented as median (range) unless otherwise indicated.
  2. CR, complete response; AHD, antecedent hematologic disease.
  3. aIn AML and MDS, cytogenetic status was categorized as favorable (t(8;21), t(15;17), inv16)); unfavorable (−5/−7, 11q); or intermediate (others). For patients with ALL, cytogenetic status was categorized as favorable (hyperdiploidy), unfavorable (Philadelphia chromosome-positive), or intermediate (others).